CRP and familial hypercholesterolemia: As previously mentioned, the JUPITER trial [65] aimed to assess the potential benefit of rosuvastatin in reducing stroke occurrence among patients exhibiting a C-reactive protein (CRP) increase (>2 mg/L) but without hypercholesterolemia.